Compare AUDC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUDC | ESPR |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.0M | 731.9M |
| IPO Year | 2000 | 2013 |
| Metric | AUDC | ESPR |
|---|---|---|
| Price | $8.36 | $2.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $12.50 | $7.60 |
| AVG Volume (30 Days) | 102.1K | ★ 5.0M |
| Earning Date | 05-05-2026 | 03-10-2026 |
| Dividend Yield | ★ 4.83% | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $403,135,000.00 |
| Revenue This Year | $4.24 | $2.92 |
| Revenue Next Year | $2.18 | N/A |
| P/E Ratio | $23.06 | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $6.95 | $0.73 |
| 52 Week High | $11.48 | $4.18 |
| Indicator | AUDC | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 54.58 | 45.15 |
| Support Level | $8.13 | $2.66 |
| Resistance Level | $8.75 | $3.02 |
| Average True Range (ATR) | 0.23 | 0.19 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 39.59 | 63.04 |
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.